Product image of Milrinone Stragen (Milrinone) supplied by GNH India

Milrinone Stragen

Active Ingredient:
Milrinone
Origin:
EU

Milrinone Stragen (Milrinone)

Milrinone, the active ingredient in Milrinone Stragen, is a phosphodiesterase‑3 (PDE3) inhibitor presented as an intravenous solution for intravenous administration. It is used to improve cardiac output in patients with acute decompensated heart failure or cardiogenic shock, providing inotropic support and vasodilation in critical care settings.

GNH India supplies Milrinone Stragen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, and specialty clinics worldwide, ensuring quality and regulatory compliance for critical care medicines through reliable logistics and validated cold‑chain handling where required.

Manufacturer / TM Owner

Stragen France

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Milrinone is a phosphodiesterase‑3 inhibitor used in the management of severe cardiac dysfunction.

  • Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion.
  • Cardiogenic shock: provides rapid inotropic support to maintain systemic perfusion.
  • Post‑cardiac surgery low‑output syndrome: enhances myocardial contractility and helps stabilize hemodynamics.

How It Works

  • Milrinone selectively inhibits the enzyme phosphodiesterase‑3, leading to accumulation of cyclic AMP within cardiac myocytes and vascular smooth‑muscle cells. Elevated cAMP increases calcium influx in heart muscle, producing a positive inotropic effect, while simultaneously causing vasodilation through smooth‑muscle relaxation, thereby improving cardiac output and reducing afterload.

Side Effects

Milrinone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Hypotension: reduction in blood pressure.
  • Arrhythmias: irregular heart rhythms.
  • Headache: mild to moderate intensity.
  • Nausea: occasional gastrointestinal upset.
  • Flushing: warmth and redness of skin.
  • Tachycardia: increased heart rate.

Serious or Rare Side Effects

  • Severe hypotension: profound drop in blood pressure.
  • Ventricular arrhythmias: life‑threatening heart rhythm disturbances.
  • Myocardial ischemia: reduced blood flow to heart muscle.
  • Thrombocytopenia: low platelet count.
  • Allergic reactions: rash, itching, or anaphylaxis.
  • Elevated liver enzymes: potential hepatic involvement.

Precautions & Warnings

Milrinone requires careful monitoring and specific safety measures before and during therapy.

  • Monitor blood pressure: watch for hypotension.
  • Assess cardiac rhythm: observe for arrhythmias.
  • Adjust dose in renal impairment: reduce or monitor renal function.
  • Avoid use in severe aortic stenosis: risk of excessive hypotension.
  • Pregnancy: use only if benefits outweigh potential risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Milrinone can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Concurrent use with other potent vasodilators: may cause severe hypotension.
  • Co‑administration with strong CYP3A4 inhibitors: increase plasma levels.
  • Use with other inotropes (e.g., dopamine) without monitoring: risk of arrhythmia.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may blunt inotropic effect.
  • Diuretics: additive effect on blood pressure.
  • Anticoagulants: monitor for bleeding if hypotension occurs.

Frequently Asked Questions

Milrinone Stragen is an intravenous inotropic agent indicated for the treatment of acute decompensated heart failure and cardiogenic shock. It provides positive inotropic support and vasodilation to improve cardiac output in critically ill patients.

Milrinone selectively inhibits phosphodiesterase‑3, leading to increased intracellular cyclic AMP. The rise in cAMP enhances calcium entry into cardiac myocytes, producing stronger contractions, while also relaxing vascular smooth muscle, which reduces afterload.

The dosing regimen for Milrinone Stragen is determined by the prescribing clinician based on the patient’s hemodynamic status, renal function, and therapeutic response. It is administered intravenously under continuous monitoring in a hospital setting.

Safety of Milrinone in pregnancy and lactation has not been established. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under specialist supervision.

Submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and import documentation.

Compared with agents such as dopamine or dobutamine, Milrinone offers both inotropic support and vasodilation via PDE3 inhibition, which can lower afterload. However, it may carry a higher risk of hypotension and requires careful blood‑pressure monitoring.

Milrinone Stragen should be stored at 2‑8 °C, kept refrigerated, protected from light, and never frozen or shaken. Inspect the container for any damage before use and discard after the labeled expiry date.

Milrinone is supplied as an intravenous solution that is infused through a controlled IV pump. A loading dose may be given initially, followed by a continuous infusion that is titrated according to blood pressure, heart rate and cardiac output.

The most critical adverse events include severe hypotension, ventricular arrhythmias, myocardial ischemia and thrombocytopenia. Immediate medical attention is required if any of these serious reactions are observed during therapy.

Milrinone should be avoided in patients with known hypersensitivity to the drug, severe aortic stenosis, uncontrolled ventricular arrhythmias, or any condition where a significant drop in blood pressure would be hazardous.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Milrinone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT